DLL3 and posterior cortical atrophy: The 89Zr-labeled DLL3-targeting antibody SC16 (89Zr-deferoxamine-SC16) facilitates noninvasive detection of DLL3-positive NEPC lesions via PET imaging [101], while CEACAM5-targeted immuno-PET agents enable in vivo visualization of AR-negative PCa subtypes.